FOFO:NASDAQHang Feng Technology Innovation Co., Ltd. Analysis
Data as of 2026-06-13 - not real-time
$2.86
Latest Price
8/10Risk
Risk Level: High
Executive Summary
FOFO is trading at $2.86, well below its 20‑day (3.00), 50‑day (3.38) and 200‑day (8.13) simple moving averages, signaling a pronounced bearish bias. The MACD histogram is negative and the signal line is bearish, while the RSI sits near 47, indicating no momentum to reverse the downtrend. Volume is increasing, yet price continues to slide, and the 30‑day volatility exceeds 250%, reflecting an extremely erratic price path. The stock has endured a historic drawdown of nearly 96%, underscoring the depth of its recent weakness.
Fundamentally, the company posted a 44% revenue contraction, negative operating margins (‑10.2%), and an EBITDA loss exceeding $9.7 M, with zero earnings per share. Cash on hand (~$7.4 M) is modest relative to its market cap (~$21.6 M) and a debt‑to‑equity ratio of 1.56, suggesting limited financial cushion. Valuation multiples (price‑to‑book 2.5×, price‑to‑sales 9.3×) appear stretched given the lack of profitability. Operating in the Hong Kong consulting segment adds medium regulatory and geopolitical exposure, while the high beta (1.14) and thin trading volumes raise liquidity concerns. Overall, the technical picture is bearish, the fundamentals are deteriorating, and the risk profile is elevated, leading to a cautious outlook.
Fundamentally, the company posted a 44% revenue contraction, negative operating margins (‑10.2%), and an EBITDA loss exceeding $9.7 M, with zero earnings per share. Cash on hand (~$7.4 M) is modest relative to its market cap (~$21.6 M) and a debt‑to‑equity ratio of 1.56, suggesting limited financial cushion. Valuation multiples (price‑to‑book 2.5×, price‑to‑sales 9.3×) appear stretched given the lack of profitability. Operating in the Hong Kong consulting segment adds medium regulatory and geopolitical exposure, while the high beta (1.14) and thin trading volumes raise liquidity concerns. Overall, the technical picture is bearish, the fundamentals are deteriorating, and the risk profile is elevated, leading to a cautious outlook.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Price below all major SMAs indicating strong bearish trend
- Negative MACD histogram and bearish signal line
- Extreme volatility and historic near‑100% drawdown
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Absence of earnings and negative margins limit upside
- Modest cash reserves provide limited runway
- Potential upside if the firm secures new consulting contracts
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Company is newly founded (2023) with uncertain growth trajectory
- Valuation remains high relative to earnings‑free fundamentals
- Persistent high beta and liquidity constraints elevate long‑term risk
Key Metrics & Analysis
Financial Health
Revenue Growth-44.10%
ROE-151.93%
ROA-81.13%
Debt/Equity1.56
P/B Ratio2.5
Op. Cash Flow$-1289230
Free Cash Flow$-3853934
Industry P/E30.6
Technical Analysis
TrendBearish
RSI47.0
Support$1.75
Resistance$8.45
MA 20$3.00
MA 50$3.38
MA 200$8.13
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta1.14
Volatility257.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.